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Tau is primarily a neuronal microtubule-associated protein that has functions related to the stabilisation of microtubules.
Phosphorylation of tau is an important dynamic and regulatory element involved in the binding of tau to tubulin. Thus, highly
phosphorylated tau is more likely to be present in the cytosolic compartment of neurons, whereas reduced phosphate burden
allows tau to bind to and stabilise the microtubule cytoskeleton. Highly phosphorylated forms of tau are deposited in the brain
in a range of neurodegenerative disorders including Alzheimer’s disease, progressive supranuclear palsy, and frontotemporal lobar
degeneration associated with Pick bodies. A key candidate kinase for both physiological and pathological tau phosphorylation is
glycogen synthase kinase-3 (GSK-3). Multiple phosphorylation sites have been identiﬁed on tau exposed to GSK-3 in vitro and
in cells. In this review, we highlight recent data suggesting a role for GSK-3 activity on physiological tau function and on tau
dysfunction in neurodegenerative disease.
1.Introduction
The microtubule-associated protein tau is a normally soluble
phosphoprotein found predominantly in neurons [1]. The
structure of tau comprises three broadly deﬁned regions, an
N-terminal projection domain, that is thought to be respon-
sibleforitsinteractionwithmembranesandotherproteins,a
central proline-rich domain, and a C-terminal microtubule-
binding repeat region (Figure 1). Phosphorylation of tau
is usually a very rapid and reversible process, which is
mediated by the opposing actions of several protein kinases
and phosphatases [2]. Tau phosphorylation is increased
during embryonic development, and in neurodegenerative
conditions, in which tau deposition is a characteristic
feature [3, 4]. Such disorders include Alzheimer’s disease,
progressive supranuclear palsy (PSP), and frontotemporal
lobar degeneration associated with Pick bodies, amongst
others, collectively termed the “tauopathies”. A common
factor to all of these diseases is the presence of aggregated
and highly phosphorylated tau in the brain. These aggregates
characteristically form intracellular inclusions comprised
predominantly of tau with reduced solubility and increased
reactivity to phospho-speciﬁc tau antibodies. Determining
the key kinases that may be involved in the development and
progression of disease pathology is an important research
goal. In this review, we highlight the links between glycogen
synthase kinase-3 (GSK-3) activity and tau function in
normal and diseased brain.
2.The Microtubule-AssociatedProteinTau
2.1. Tau Function and Localisation. Tau is present in the
adult human central nervous system (CNS) as six isoforms
that are generated from alternative splicing of a single gene.
These isoforms diﬀer from each other by the presence
of none, one, or two inserts of 29 amino acids in the
N-terminus of the molecule, and the inclusion of either
three (3R) or four (4R) repeated stretches of approximately
30 amino acids that comprise the microtubule-binding
region of the molecule (Figure 1). Tau in embryonic brain
comprises primarily the smallest (0N3R) tau isoform, and
this single isoform is gradually replaced with the six adult2 International Journal of Alzheimer’s Disease
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Figure 1:TauisoformsinthehumanCNSandidentiﬁedGSK-3phosphorylationsites.Thediagramillustratesthesixisoformsoftaupresent
in the human CNS. The longest tau isoform includes alternatively spliced exons 2, 3, and 10. Exons 2 and 3 encode two short amino acid
inserts near the N-terminus of the molecule (1N and 2N, respectively). Exclusion of exons 2 and 3 gives rise to 0N tau isoforms, inclusion of
exon 2 produces 1N tau isoforms, and inclusion of exons 2 and 3 results in the expression of 2N tau isoforms. Exon 10 encodes an additional
microtubule-binding repeat domain (R2) that is present in 4R, but absent from 3R, tau isoforms. The number of amino acids in each tau
isoform is indicated on the right. The centre of the molecule comprises a proline-enriched region that harbours the majorityof the identiﬁed
GSK-3 phosphorylation sites in 2N4R tau. Serine (S) and threonine (T) residues that have been identiﬁed as being phosphorylated by GSK-3
in vitro are indicated below.
isoforms during development [5, 6]. In normal adult human
brain, the ratio of the tau isoforms harbouring three or
four microtubule-binding repeats is approximately equal.
However,thisratioisalteredinfavourofexpressionofthe4R
tau isoforms in several neurodegenerative tauopathies [7],
although increased relative expression of 3R tau isoforms
has also been observed in frontotemporal lobar degeneration
associated with Pick bodies [8]. Thus, abnormal tau splicing
and phosphorylation are both events that are closely associ-
ated with neurodegeneration.
In neurons, the primary location of tau is in axons,
where it is presumed to act as a stabilising protein for the
microtubule cytoskeleton. Tau has an important function in
maintaining microtubule dynamic instability, through dual
processes that result in the lengthening and shortening of
microtubules in response to external signals [9]. Increased
tau phosphorylation leads to its detachment from tubulin,
thereby, enhancing microtubule disassembly and reducing
microtubule stability [10, 11]. In contrast, dephosphoryla-
tionoftauleadstoanincreaseinitsbindingtotubulin,accel-
erated microtubule growth, and stabilisation of the micro-
tubule cytoskeleton. Altered microtubule stability is partic-
ularly important during neurodevelopment when increased
phosphorylation of tau reduces its binding to microtubules,
allowing the rapid extension and retraction of exploratory
neurites. Spatial and temporal changes in tau phosphory-
lation have been reported during neuronal diﬀerentiation
[12], and some phosphorylated epitopes on tau (e.g., PHF-
1, corresponding to phosphorylated Ser396/Ser404 in tau)
have been associated with early stages of axon formation
[13], indicating a role for tau in the development of neuronal
polarity. In disease, highly phosphorylated forms of tau
bind less well to microtubules, resulting in a loss of the
microtubule-stabilising properties of tau and ultimately the
collapse of the neuronal cytoskeleton. This has the eﬀect of
disrupting axonal transport and negatively impacting on the
delivery of organelles, neurotransmitters, and other proteins
to and from the cell body, with a consequent detrimental
eﬀect at synaptic termini [14–16].
Tau phosphorylation also inﬂuences the positioning of
tau in dendrites, and the association of tau with plasma
membranes and nuclei. Elevated phosphorylation results in
the relocalisation of tau from axons into the somatodendritic
region of neurons. Interactions between tau and the non-
receptor tyrosine kinase, Fyn, result in increased Fyn local-
isation in dendrites [17]. In models of Alzheimer’s disease,
increased Fyn activity in response to neurotoxic stimuli such
as β-amyloid (Aβ), enables Fyn to phosphorylate subunit
2B (NR2B) of the N-methyl-D-aspartate (NMDA) receptor,
increasing the stability of this complex with the postsynaptic
density (PSD) protein, PSD-95, and ultimately enhancing
neurotoxicity [17]. In contrast, dephosphorylation of tau
increases its association with plasma membranes [18, 19],
which may also inﬂuence neurodegenerative processes byInternational Journal of Alzheimer’s Disease 3
Table 1:ComparisonofphosphorylationsitesinhumanAlzheimer
and control brain with recombinant tau phosphorylated by GSK-3
in vitro.
Tau residue number Alzheimer tau Control brain tau GSK-3
Tyr18 A
Ser46 A ••
Thr50 •
Ser68 •
Thr69 ••
Thr71 •
Ser113 •
Thr123 A
Ser131
Thr149 •
Thr153 A •
Thr175 ••
Thr181 •• •
Ser184 ••
Ser185 •
Ser191 •
Ser195 •
Tyr197 •
Ser198 •• •
Ser199 •• •
Ser202 •• •
Thr205 A ••
Ser208 •
Ser210 ••
Thr212 •• •
Ser214 ••
Thr217 •• •
Thr220 •
Thr231 •• •
Ser235 •• •
Ser237 ••
Ser238 •
Ser241 •
Thr245 •
Ser258 ••
Ser262 ••
Ser285 •
Ser289 ••
Ser305 •
Ser324 •
Ser352 •
Ser356 ••
Thr373 •
Tyr394 •
Ser396 •• •
Ser400 •• •
Thr403 •
Ser404 •• •
Table 1: Continued.
Tau residue number Alzheimer tau Control brain tau GSK-3
Ser409 ••
Ser412 •∗ ∗
Ser413 •∗ ∗ •
Thr414 ∗∗ ∗
Ser416 A∗ •
Ser422 •
Thr427 •
Ser433 •
Ser435 •
Numbering of residues refers to 2N4R human tau, the largest isoform
present in the human CNS.
•indicates tau phosphorylation sites identiﬁed by direct means.
A indicates tau phosphorylation sites identiﬁed using phospho-speciﬁc tau
antibodies.
∗ indicates that one of the two closely spaced phosphorylation sites
indicated (Thr414, Ser416) is phosphorylated in tau from AD brain.
∗∗ indicates that two of the three closely spaced phosphorylation sites
indicated (Ser412, Ser413, Thr414) are phosphorylated in tau from control
human brain.
mediating the interactions of tau with membrane-associated
cell-signalling molecules such as Src-family kinases and
phospholipase C-γ [20–22].
A pool of tau has also been identiﬁed in the nucleus
of cultured cells and in brain tissue [23–28]. In human
neuroblastoma cells, tau has been identiﬁed in the nucleolar
organiser region [23], and, thus, tau-DNA binding may be
involved in nucleolar organisation [27]. It has been reported
that the phosphorylation of tau, particularly in response to
heat stress, increases the amount of tau found in neuronal
nuclei [29], although this ﬁnding is somewhat controversial
[30].Themicrotubule-bindingdomainoftauassociateswith
RNA [31]a n dD N A[ 32], and the association of nuclear tau
with DNA in response to stress is believed to play a role
in protecting DNA from damage [29]. Tau has been found
to be associated with the, predominantly nuclear protein,
mammalian solute transport protein-2 (SUT2). SUT2 is
localised to SC35-positive speckles in the nucleus, and it
may have a role in mRNA processing [33]. Expression of
this protein in C. elegans potentiates tau neurotoxicity [34,
35]. In addition, mammalian SUT2 is reduced in disease-
aﬀected regions of Alzheimer brain, under conditions where
tau phosphorylation is increased, and SUT2 expression is
increased when tau is overexpressed in mammalian cells in
culture [34]. RNAi knockdown of SUT2 in cultured human
cells overexpressing tau results in a marked decrease in tau
aggregation, with no apparent eﬀect on soluble tau species,
suggesting a possible role for SUT2 in the pathogenesis of
tauopathies [34]. Thus, tau may mediate neurodegeneration
by changes in phosphorylation that result in both losses and
gains of tau function.
2.2. Tau Phosphorylation. Tau possesses 80 phosphorylatable
serine and threonine residues, approximately 20% of which
have been identiﬁed as being phosphorylated in normal
human brain (Table 1). A further ﬁve tyrosine residues in4 International Journal of Alzheimer’s Disease
tauarealsoamenabletophosphorylationbytyrosinekinases,
including Fyn, Syk, c-Abl, and Lck [36, 37]. A large number
of serine/threonine kinases have been reported to phospho-
rylate tau in vitro, but the identity of the protein kinase(s)
responsible for regulating physiological tau phosphorylation
remains unknown [7]. Candidate serine/threonine-directed
taukinasesincludeGSK-3,caseinkinase1(CK1),andcyclin-
dependent kinase-5 (cdk5), amongst others [7]. It seems
likely that more than one kinase may be involved in the
phosphorylation of tau. However, substantial evidence exists
to support a major role for GSK-3 in both physiological and
pathological tau phosphorylation.
3. Glycogen Synthase Kinase-3
3.1. GSK-3 Isoforms. GSK-3 exists as two isoforms, α and
β, which share 85% sequence identity and are encoded by
distinctgeneslocatedonchromosomes19and3,respectively
[38]. GSK-3α and GSK-3β both phosphorylate tau in vitro
and appear as granules with slightly diﬀering morphologies
and densities in pyramidal cells of hippocampal neurons
[39]. There are two variants of GSK-3β,w i t hG S K - 3 β2
diﬀering from GSK-3β1 by the presence of an additional
insertionof13aminoacids.GSK-3β2isenrichedinneurons,
where it is present in cell bodies, neuritis, and growth cones
[40]. GSK-3α and GSK-3β share many substrates and appear
to be able to compensate partially for each other, although
they also appear to have distinct functions [41]. A recent
report has shown that, whereas GSK-3β is present in birds,
GSK-3α is absent, indicating that the GSK-3α isoform is
not required either for viability or for normal physiological
function in birds [42]. Furthermore, knockout of GSK-3α in
mice results in increased insulin sensitivity [43], suggesting
ar o l ef o rG S K - 3 α in glucose metabolism that cannot be
replaced by GSK-3β.Incontrast,completeknockoutofGSK-
3β in mice is embryonic lethal [44].
3.2. Regulation of GSK-3 Activity. The kinase activity of
GSK-3 is regulated by its phosphorylation at serine and
tyrosine residues. Phosphorylation of GSK-3α/β at Tyr216
and Tyr279 is believed to maintain the constitutive activity
of GSK-3 in neurons (reviewed in [45]), while the phospho-
rylation of Ser21 on GSK-3α or Ser9 on GSK-3β negatively
regulates GSK-3 activity [45], and phosphorylation at these
residues is believed to the predominant mediator of GSK-3
activity in vivo [46]. Both protein phosphatase 1, (PP1) and
PP2A are known to target Ser21/9 and thus regulate GSK-3
activity [47]. Indeed, PP activation with okadaic acid leads
to increased phosphorylation of S9 and, hence, inhibition
of GSK-3β, which results in reduced tau phosphorylation
[48]. Other phosphatases could also be involved in GSK-3
regulation since calcineurin (PP2B) also dephosphorylates
andhenceactivatesGSK-3[49].Inaddition,oneofthemany
substrates of GSK-3 is the inhibitory subunit (inhibitor-2)
of PP1. The phosphorylation of this subunit leads to its
activation which results in the inhibition of PP1 [50], and
decreased GSK-3 activity, demonstrating one mechanism
through which GSK-3 activity may be regulated.
3.3. GSK-3 Regulation of Tau Splicing. In addition to phos-
phorylating tau, GSK-3 can inﬂuence tau splicing. GSK-3
has been shown to phosphorylate nuclear SC35, an enhancer
of splicing elements that regulate exon 10 splicing in tau
[51, 52]. Aβ application to cultured cells activates GSK-3
[53], leading to the phosphorylation of SC35 in parallel with
enhanced splicing of tau exon 10 and decreased expression
of 4R tau [54]. These events can be suppressed by the
inhibition of GSK-3 activity with lithium or following siRNA
knockdown of GSK-3 [54]. Despite these ﬁndings, most
research investigating GSK-3 regulation of tau function has
concentrated on GSK-3-mediated phosphorylation of tau.
3.4. GSK-3 Regulation of Tau Phosphorylation. Tau is a
good substrate for GSK-3 in vitro [39, 55], in cultured
nonneuronal cells [56], and in transgenic mice overex-
pressing GSK-3 [57]. In brain, tau exists in a complex
with GSK-3 and the scaﬀolding protein 14-3-3 [58]. 14-
3-3 recognises GSK-3 phosphorylated at Ser9, and indeed
GSK-3 in this complex is phosphorylated at Ser9 in brain
[58, 59]. The association of tau with this complex is believed
to regulate its phosphorylation by GSK-3, since in human
embryonic kidney cells, tau phosphorylation by GSK-3 is
suppressed in the absence of 14-3-3, but GSK-3 is active and
phosphorylates tau if 14-3-3 is present [59].
4.In vitro Phosphorylation of Tau by GSK-3
Tau is phosphorylated by GSK-3 on approximately 40
diﬀerent serine and threonine residues, at least in vitro
[60, 61]. The importance of this ﬁnding should not be
underestimated since few kinases have been shown to target
this number of sites in tau. Indeed, CK1 is the only other
kinase that has been reported to phosphorylate a similar
number of tau residues. Treatment of primary neuronal
cortical cultures with speciﬁc inhibitors of either GSK-3
or CK1 reduces tau phosphorylation, suggesting that these
kinases could have functionally important roles in neurons
[7,14,60].ThephosphorylationoftaubyGSK-3orCK1also
reduces the ability of tau to promote microtubule assembly
in vitro and in cells [62, 63]. These results rank GSK-3 and
CK1 as targeting the greatest number of phosphorylatable
residues on tau and implicate these two protein kinases in
physiological tau phosphorylation in neurons. It remains
to be seen whether the activities of GSK-3 and/or CK1 are
modiﬁed in diseases in which increased phosphorylation of
tau is a characteristic feature.
4.1. Potential Priming of Tau for GSK-3 Phosphorylation.
It is well established that GSK-3 preferentially phos-
phorylates many of its substrates after they have been
prephosphorylated by other kinases, and this seems also to
be true for tau phosphorylation by GSK-3. Other examples
of GSK-3 substrates that require prephosphorylation by
anotherkinasebeforerecognitionbyGSK-3includeglycogen
synthase, inhibitor-2 of PP1, the regulatory subunit of cyclic
AMP-dependent protein kinase (PKA), cAMP response
element-binding (CREB), β-catenin, and kinesin light chain
[46, 64]. Most priming phosphorylations for GSK-3 occur atInternational Journal of Alzheimer’s Disease 5
an amino acid located four residues C-terminal to the target
residue [65]. However, there are some exceptions to this rule,
and priming events have been reported that occur ﬁve or six
residues from the GSK-3 target site, for example, in collapsin
response mediator protein-2 and also in tau [66, 67]. The
GSK-3 priming phosphorylation is frequently provided by
the activity of PKA, CK1, or CK2 on unphosphorylated
substrates, although other kinases, such as members of the
mitogen-activated protein kinase family, or cdk5, can also
initiate priming on some GSK-3 substrates [68, 69]. As has
previously been shown, CK1 primes β-catenin for subse-
quent phosphorylation by GSK-3 (reviewed in [69]), and
this might also occur on tau because the rate of GSK-3 phos-
phorylationoftauisincreasedwhenitisﬁrstphosphorylated
by CK1 [70]. Substrate priming, therefore, may represent an
important regulatory element of GSK-3 signalling since the
activity of GSK-3 has been reported to diﬀer for its primed
and nonprimed substrates [68]. In the case of tau, this is
supported by the observation that targeting GSK-3 phos-
phorylation of tau to either unprimed or primed sites has
ad i ﬀerential impact on the binding of tau to microtubules
[71, 72].
There are 24 short sequences of amino acids in tau
that conform to the strict consensus sequence Ser/Thr-XXX-
Ser/Thr (indicating pairs of serine or threonine residues
separatedbyanythreeaminoacids),thatcouldbeimplicated
in priming for GSK-3. Fourteen of these serine/threonine
pairs have been found to be phosphorylated in vitro by
GSK-3 (Table 1), and six pairs contain a proline residue
immediately C-terminal to the target sequence. Five of the
10 remaining paired amino acids are phosphorylated by
GSK-3 on only one of the two serine or threonine residues
and ﬁve pairs have not been shown to be phosphorylated
by GSK-3. Relaxation of the consensus sequence to include
a separation of ﬁve or six amino acids between potential
priming sites would allow the inclusion of further sets
of amino acids, including Ser214, Ser210, Thr205, and
Ser199 (see below). Overall, therefore, tau appears to fulﬁl
several of the requirements for GSK-3 substrates, including
multiple Ser/Thr-Pro sequences with nearby N-terminal
phosphorylatable amino acids closely opposed, which could
allow for kinase priming, either by GSK-3 itself or by other
tau kinases.
Priming phosphorylation on tau residues Ser235 and
Ser404 by other kinases, including cdk5, has been shown to
promote phosphorylation by GSK-3 at Thr231 and Ser400,
respectively [71, 72]. Interestingly, the stretch of amino acids
in tau that includes the phosphorylatable residues, Ser396,
Ser400, and Ser404, can be directly phosphorylated by GSK-
3 without the prior activity of other kinases [67]. However,
phosphorylation at Ser404 is critical to this process and
substitution of this residue by alanine ablates phosphoryla-
tion of both Ser396 and Ser400. It appears, therefore, that
the primary phosphorylation of Ser404 by GSK-3 can itself
serve as a primed residue for the subsequent sequential
phosphorylation of tau at Ser400 and Ser396 by GSK-3.
However, the functional signiﬁcance of many of the other
potential GSK-3 priming sites in tau has not been widely
investigated.
Prephosphorylation of tau by PKA for subsequent GSK-
3 phosphorylation in rat brain appears to particularly
enhance the overall amount of GSK-3 phosphorylation [73].
Furthermore, the initial phosphorylation of tau by PKA
results in a diﬀerent spectrum of phosphorylation sites gen-
erated by the action of GSK-3 compared to those produced
when tau is exposed to GSK-3 alone, demonstrating that
prior phosphorylation by PKA alters the recognition of
tau by GSK-3 [73]. Moreover, initial phosphorylation of
tau by PKA, which occurs primarily on Ser214, results in
the subsequent phosphorylation by GSK-3 of four closely
spaced residues, namely Ser210, Thr205, Ser199, and Ser195,
each separated by 4–6 amino acids [67]. Interestingly, this
study also revealed an interaction between the low-density
lipoprotein receptor-binding domain of apolipoprotein E
(ApoE), a major genetic risk factor for Alzheimer’s disease,
and GSK-3-phosphorylated tau [67]. Such an interaction
was not observed with either nonphosphorylated tau or
following extensive phosphorylation of tau by PKA. These
results suggest that the pattern of phosphorylation sites
generated by the action of GSK-3 on tau may be critical for
its interaction with ApoE.
4.2. GSK-3α and GSK-3β1/2 Isoforms Diﬀerentially Phospho-
rylate Tau. Suppressing the expression of individual GSK-
3α and GSK-3β isoforms results in diﬀering tau phospho-
rylation patterns [74]. The induction of a phosphorylation-
induced shift in electrophoretic mobility of tau, follow-
ing incubation with GSK-3, also appears to be favoured
preferentially by GSK-3β, rather than GSK-3α,a si st a u
phosphorylation at the antibody epitopes recognised by tau-
1 (Ser199–Ser202) and 8D8 (Ser396) [39]. Together, these
results support the view that GSK-3α and GSK-3β are likely
to have diﬀering preferences for tau that may be related to
the distinct, but overlapping, intracellular locations of these
kinases in neurons.
There is also a diﬀerence in the kinetics and sites of
tau phosphorylation induced by the two GSK-3β isoforms,
with GSK-3β2 appearing to phosphorylate tau more slowly
than GSK-3β1 and on diﬀerent, with some overlapping,
tau residues, even under conditions in which other GSK-
3β substrates, such as amyloid precursor protein, are phos-
phorylated equally [75, 76]. For example, Ser396 in tau is
phosphorylated by both splice variants, whereas Ser199 is a
signiﬁcant target of GSK-3β1, but not of GSK-3β2a c t i v i t y .I t
has recently been suggested that the interaction of GSK-3β2
withtauisweakerthanthatofGSK-3β1[76].Takentogether,
these results suggest that, not only are there diﬀerential
activities of GSK-3α and GSK-3β towards tau, there are
also partially overlapping, but distinct, tau phosphorylation
sites recognised by each of the two isoforms of GSK-3β
[74–77].
5. Tau Phosphorylation in Human Brain
In the tauopathies, tau is present in both normally phospho-
rylated and highly phosphorylated forms, the latter of which
may be potentially pathological since it is most commonly
observed as intraneuronal aggregates or glial inclusions.6 International Journal of Alzheimer’s Disease
Tau is normally a highly soluble protein under nonde-
naturing conditions, but the aggregated tau present in
diseased brain displays a signiﬁcantly reduced solubility and
an increased reactivity to phospho-speciﬁc tau antibodies
[78]. These characteristic features have facilitated puriﬁca-
tion strategies for tau from diseased brain exhibiting tau
pathology which yield relatively enriched preparations of
highly phosphorylated tau. Such preparations have resulted
in the identiﬁcation of phosphorylation sites on insoluble
tau isolated from human tauopathy brain, thereby providing
clues to the identities of protein kinases that are potentially
involved in the pathogenesis or development of these
neurodegenerative diseases [60, 79–81].
In particular, these approaches have been used to identify
phosphorylation sites on puriﬁed tau from Alzheimer’s
disease and PSP brain material, as well as soluble tau from
control adult and foetal brain [60, 82, 83]. These studies,
combined with results obtained from immuno-labelling
with phospho-speciﬁc tau antibodies, have led to the
identiﬁcation of approximately 45 phosphorylation sites on
tau from Alzheimer brain (Table 1). In comparison, only 15
phosphorylation sites have been detected in insoluble tau
from PSP brain and 16 sites on control brain tau, not all of
which overlap, and for some of which no kinase has yet been
identiﬁed [7].
A comparison of tau extracted from human brain with
tau phosphorylated using protein kinases in vitro shows that
GSK-3 remains a principal candidate kinase for both phys-
iological and pathological tau phosphorylation (Table 1).
Although GSK-3 has been reported to be associated with
neuroﬁbrillary pathology in Alzheimer’s disease and related
neurodegenerative disorders [84, 85] ,o t h e rs t u d i e sh a v en o t
identiﬁed such colocalisation [39, 86], and it remains to
be seen if GSK-3 remains associated with tau pathology in
diseased brain. In the case of tau extracted from neurolog-
ically normal human brain, all but two residues have been
shown to be phosphorylated by GSK-3. These two sites,
Ser412 and Thr414, are located within a group of three
closely spaced residues, including Ser413, of which only two
residues are phosphorylated in human brain. Since GSK-
3 phosphorylates Ser413, it is possible that only a single
site, either Ser412 or Thr414, remains unphosphorylated
by GSK-3, and, of these, Ser412 is phosphorylated by both
CK1 and PKA, and potentially also by CK2. This suggests
that, under physiological conditions, tau in human brain
may be phosphorylated primarily by GSK-3, with potential
contributions from CK1, CK2, or PKA. Under pathological
conditionssuchasAlzheimer’sdisease,inwhichtaubecomes
deposited in the brain, GSK-3 accounts for some 27 of
the approximately 45 tau phosphorylation sites identiﬁed
in insoluble tau. The remaining phosphorylation sites are
accountedfortheactivitiesofacombinationofotherkinases,
including the tyrosine kinases, c-Abl, and Fyn, although
there remain a few sites for which a kinase has not yet been
identiﬁed. Thus GSK-3 plays a prominent role in both the
physiological and pathological phosphorylation of tau in
human brain.
6. Cellular Models of Tau
Phosphorylation by GSK-3
Further information regarding the role of GSK-3 in tau
phosphorylation and function has been gained from cell
models. In cells, the involvement of GSK-3 was ﬁrst revealed
when GSK-3 over-expression was shown to disrupt tau
binding to microtubules, resulting in a diﬀuse cytoplasmic
localisation of tau [56]. This staining pattern contrasts with
the strongly ﬁbrillar pattern displayed when tau is expressed
alone. Cellular phosphorylation of tau by GSK-3β over-
expressed in mammalian cells decreases tau binding to
microtubules and inﬂuences microtubule organisation [87,
88].Thisprocessisinhibitedbymousedishevelled-1,thereby
potentiallyimplicatingthewinglesssignallingpathwayintau
phosphorylation mediated by GSK-3 [89].
Investigations in human neuronal NT2N cells have
shown that tau phosphorylation at multiple sites recognised
by phospho-speciﬁc tau antibodies could be prevented
by lithium treatment, which inhibits GSK-3 activity [90].
Lithium also promotes tau binding to microtubules and sub-
sequent microtubule polymerisation, suggesting a role for
GSK-3 in this normal physiological process [90]. It is impor-
tant to note that lithium is not a speciﬁc inhibitor of GSK-
3 as it also eﬀectively inhibits inositol monophosphatase, as
wellasafamilyofstructurallyrelatedphosphomonoesterases
(reviewed in [91]). However, the reported eﬀects of lithium
on tau phosphorylation in cells have subsequently been
validated in studies using more selective GSK-3 inhibitors
[74, 92, 93]. The examination of endogenous tau phospho-
rylation by GSK-3 in primary rat neurons has revealed a
numberoflithium-sensitivesites,suggestingthatthesemight
represent the physiological targets of GSK-3 on tau [14, 94].
Interestingly, in the latter study, the inhibition of GSK-3,
either by lithium or by the more speciﬁc GSK-3 inhibitor,
SB-415286,resultednotonlyinreducedtauphosphorylation
but also in reduced axonal transport of tau [14]. This led to
the idea that tau phosphorylation mediated by GSK-3 could
inﬂuence tau axonal transport, at least in primary neuronal
cultures [14]. In an ex vivo study, perfusion of preformed
ﬁlaments of tau into isolated squid axoplasm resulted in
the inhibition of anterograde transport of membrane-bound
organelles [95]. Interestingly, inhibiting GSK-3 activity, or
perfusion of inhibitor-2 to inhibit PP1 activity, overcame the
detrimental eﬀect of tau ﬁlaments on axonal transport in
this model [95]. These results, thus, support the notion that
GSK-3 has an important role in relation to tau function in
neurons.
Inhibiting GSK-3 with SB-415286 also protects cultured
neurons from cell death induced by reduced phosphatidyli-
nositol 3-kinase activity, and this protection is paralleled by
decreased tau phosphorylation [92]. These results suggest
that the state of tau phosphorylation by GSK-3 in cells
is important for the maintenance of healthy functional
neurons, and changes in tau phosphorylation are likely be
indicative of reduced neuronal viability.International Journal of Alzheimer’s Disease 7
7. AnimalModels of Tau
Phosphorylation by GSK-3
7.1. Drosophila. Over-expression of tau together with GSK-
3 (the human orthologue of shaggy/Zw3 in Drosophila)
has been demonstrated to exacerbate the neurodegenera-
tion resulting from expression of tau alone in Drosophila
melanogaster [96], suggesting that the phosphorylation
of tau by GSK-3 is involved in the neurodegenerative
process. The presence of partition-defective 1 (PAR-1), the
Drosophila orthologue of mammalian microtubule aﬃnity
regulating kinase (MARK), has been shown to be required
to initiate GSK-3 and cdk5 phosphorylation of tau in
ﬂies [97]. However, reports diﬀer as to whether PAR-
1 activity enhances [97, 98] or suppresses [15, 99, 100]
tau-induced toxicity, although PAR-1 over expression in
Drosophila appears to increase neuronal loss [97]. MARK
phosphorylates tau on Ser262 and Ser356 in vitro,b o t ho f
which are located within the microtubule-binding domain
of tau, and this phosphorylation results in the disruption
of microtubules [101]. MARK phosphorylation, therefore,
results in the detachment of tau from microtubules, and
this may be related to its involvement in microtubule-based
axonaltransportinneurons[102].Interestingly,MARKitself
is phosphorylated by GSK-3, resulting in MARK inactivation
[103], suggesting the possible involvement of multiple tau
kinases in this model, however the relevance GSK-3 and
MARK interaction to tau phosphorylation has not yet been
determined.
More recent studies have found that tau phosphorylation
in Drosophila is not dependent on GSK-3 activity. A mutant
form of tau, described as GSK-3 resistant, retained toxicity
in ﬂies, and, under these conditions, mutant tau exhibited an
increased aﬃnity for binding to microtubules [98]. Notably,
while GSK-3 phosphorylation of tau was impaired in these
ﬂies,toxicity wasunaﬀected,suggesting that the ability of tau
to bind to microtubules, or possibly the propensity of GSK-3
to alter the oligomerisation state of tau, may be critical for
neurodegeneration.
Drosophila express a form of tau with limited homology
to human tau, especially in the microtubule-binding region
[104]. There is less than 50% amino acid identity between
the presumed microtubule-binding domain of Drosophila
and mammalian tau. Coupled with the presence of an
additional microtubule-binding repeat in ﬂies, these consid-
erable diﬀerences between invertebrate and mammalian tau
suggest that the results obtained by overexpressing GSK-3
in ﬂies may diﬀer from those obtained in the presence of
human tau. The relationship, therefore, between tau toxicity
and tau phosphorylation in Drosophila warrants further
investigation if it is to be applied to study the physiological
relevance of GSK-3 phosphorylation of tau.
7.2. Mice. The inﬂuence of GSK-3-mediated tau phospho-
rylation in mammals has been studied in various mouse
models (reviewed in [105]). The postnatal over-expression
o fG S K - 3i nm i c er e s u l t si nG S K - 3a c t i v a t i o na n dt h e
development of several characteristics of human tauopathy
including elevated tau phosphorylation, reactive gliosis,
spatial learning deﬁcits, and neuronal death [106, 107].
These features can be reversed by suppressing GSK-3β
expression [108], indicating that tau is a prime substrate
for GSK-3 in vivo. Indeed, the axonopathy and motor
impairment resulting from over-expression of human 2N4R
tau in mice is alleviated when GSK-3β is coexpressed [109],
withthisbeneﬁcialeﬀectbelievedtooccurasaresultofGSK-
3 phosphorylation of tau removing excess tau from micro-
tubules. Further support for a potential pathological role of
GSK-3-phosphorylated tau has come from studies showing
that GSK-3 inhibition in transgenic mice expressing disease-
associated mutant human tau reduces tau phosphorylation
and aggregation [110–114]a sw e l la sa x o n a ld e g e n e r a t i o n
[111].
8. Conclusions
Changes in the phosphorylation state of tau have a major
impact on its subcellular localisation and function in
neurons. Major changes in the phosphorylation state of
tau are evident under two apparently unrelated conditions,
that is, during early neuronal development and during
neurodegenerative processes that lead to the deposition of
highly phosphorylated pathological tau in the brain, such as
in Alzheimer’s disease. Therefore, determining the nature of
the kinases involved in this process in vivo is an important
research goal that will improve our understanding of these
processes.
GSK-3 is a key candidate kinase for tau phosphorylation,
underbothphysiologicalandpathologicalconditions.Multi-
pleserineandthreonineresiduesontauaretargetedbyGSK-
3 in vitro, with many of these sites being coincident with
those phosphorylated in vivo. Together with the, possibly
coordinated, activity of other kinases, including CK1, cdk5,
PKA and/or MARK, GSK-3 is well positioned to act on tau
in such a way that will result in signiﬁcant and rapid tau
phosphorylation and, hence, modulation of its function in
neurons. Understanding the regulation of GSK-3 activity
in neurons, including the possible diﬀerential eﬀects of the
related GSK-3α,G S K - 3 β1, and GSK-3β2 isoforms, should
lead to further elucidation of the mechanisms underlying tau
phosphorylation and may ultimately lead to new therapeutic
targets for neurodegenerative disease.
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